Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Related Posts
Here are Wednesday’s biggest analyst calls: Nvidia, Apple, Capital One, Goldman Sachs, Salesforce, CrowdStrike & more
Here are Wednesday’s biggest calls on Wall Street.
Trump says any country that buys oil from Iran will not be allowed to do business with U.S.
The Trump administration believes Iran is trying to build a nuclear bomb, an allegation that the Islamic Republic has denied.
S&P 500 should reach 6,600 this year on easing inflation backdrop, says UBS
The S&P 500 snapped a three-day advance on Thursday.